555 related articles for article (PubMed ID: 21193054)
21. Reduced-intensity transplantation for lymphomas using haploidentical related donors vs HLA-matched unrelated donors.
Kanate AS; Mussetti A; Kharfan-Dabaja MA; Ahn KW; DiGilio A; Beitinjaneh A; Chhabra S; Fenske TS; Freytes C; Gale RP; Ganguly S; Hertzberg M; Klyuchnikov E; Lazarus HM; Olsson R; Perales MA; Rezvani A; Riches M; Saad A; Slavin S; Smith SM; Sureda A; Yared J; Ciurea S; Armand P; Salit R; Bolaños-Meade J; Hamadani M
Blood; 2016 Feb; 127(7):938-47. PubMed ID: 26670632
[TBL] [Abstract][Full Text] [Related]
22. Sirolimus, tacrolimus, and low-dose methotrexate as graft-versus-host disease prophylaxis in related and unrelated donor reduced-intensity conditioning allogeneic peripheral blood stem cell transplantation.
Alyea EP; Li S; Kim HT; Cutler C; Ho V; Soiffer RJ; Antin JH
Biol Blood Marrow Transplant; 2008 Aug; 14(8):920-6. PubMed ID: 18640576
[TBL] [Abstract][Full Text] [Related]
23. CD34
Barba P; Martino R; Zhou Q; Cho C; Castro-Malaspina H; Devlin S; Esquirol A; Giralt S; Jakubowski AA; Caballero D; Maloy M; Papadopoulos EB; Piñana JL; Fox ML; Márquez-Malaver FJ; Valcárcel D; Solano C; López-Corral L; Sierra J; Perales MA
Biol Blood Marrow Transplant; 2018 May; 24(5):964-972. PubMed ID: 29305194
[TBL] [Abstract][Full Text] [Related]
24. Allocation to Matched Related or Unrelated Donor Results in Similar Clinical Outcomes without Increased Risk of Failure to Proceed to Transplant among Patients with Acute Myeloid Leukemia: A Retrospective Analysis from the Time of Transplant Approval.
Rodríguez-Arbolí E; Márquez-Malaver FJ; Rodríguez-Torres N; Caballero-Velázquez T; Escamilla-Gómez V; Calderón-Cabrera C; Falantes-González JF; Solé-Rodríguez M; García-Ramírez P; Moya-Arnao M; Carreras E; Espigado-Tocino I; Pérez-Simón JA
Biol Blood Marrow Transplant; 2019 Jan; 25(1):183-190. PubMed ID: 30153492
[TBL] [Abstract][Full Text] [Related]
25. Comparing outcomes of matched related donor and matched unrelated donor hematopoietic cell transplants in adults with B-Cell acute lymphoblastic leukemia.
Segal E; Martens M; Wang HL; Brazauskas R; Weisdorf D; Sandmaier BM; Khoury HJ; de Lima M; Saber W
Cancer; 2017 Sep; 123(17):3346-3355. PubMed ID: 28452054
[TBL] [Abstract][Full Text] [Related]
26. Reduced-intensity conditioning followed by related allografts in hematologic malignancies: long-term outcomes most successful in indolent and aggressive non-Hodgkin lymphomas.
Warlick ED; Tomblyn M; Cao Q; Defor T; Blazar BR; Macmillan M; Verneris M; Wagner J; Dusenbery K; Aurora M; Bachanova V; Brunstein C; Burns L; Cooley S; Kaufman D; Majhail NS; McClune B; McGlave P; Miller J; Oran B; Slungaard A; Vercellotti G; Weisdorf DJ
Biol Blood Marrow Transplant; 2011 Jul; 17(7):1025-32. PubMed ID: 21047561
[TBL] [Abstract][Full Text] [Related]
27. Calcineurin inhibitor--free graft-versus-host disease prophylaxis with post-transplantation cyclophosphamide and brief-course sirolimus following reduced-intensity peripheral blood stem cell transplantation.
Solomon SR; Sanacore M; Zhang X; Brown S; Holland K; Morris LE; Bashey A
Biol Blood Marrow Transplant; 2014 Nov; 20(11):1828-34. PubMed ID: 25064745
[TBL] [Abstract][Full Text] [Related]
28. Comparative outcome of reduced intensity and myeloablative conditioning regimen in HLA identical sibling allogeneic hematopoietic stem cell transplantation for acute leukemia patients: a single center experience.
Goker H; Ozdemir E; Uz B; Buyukasik Y; Turgut M; Serefhanoglu S; Aksu S; Sayinalp N; Haznedaroglu IC; Tekin F; Karacan Y; Unal S; Eliacik E; Isik A; Ozcebe OI
Transfus Apher Sci; 2013 Dec; 49(3):590-9. PubMed ID: 23981652
[TBL] [Abstract][Full Text] [Related]
29. Reduced-intensity conditioning stem cell transplantation: comparison of double umbilical cord blood and unrelated donor grafts.
Chen YB; Aldridge J; Kim HT; Ballen KK; Cutler C; Kao G; Liney D; Bourdeau G; Alyea EP; Armand P; Koreth J; Ritz J; Spitzer TR; Soiffer RJ; Antin JH; Ho VT
Biol Blood Marrow Transplant; 2012 May; 18(5):805-12. PubMed ID: 22015993
[TBL] [Abstract][Full Text] [Related]
30. Reduced-intensity allogeneic transplant in patients older than 55 years: unrelated umbilical cord blood is safe and effective for patients without a matched related donor.
Majhail NS; Brunstein CG; Tomblyn M; Thomas AJ; Miller JS; Arora M; Kaufman DS; Burns LJ; Slungaard A; McGlave PB; Wagner JE; Weisdorf DJ
Biol Blood Marrow Transplant; 2008 Mar; 14(3):282-9. PubMed ID: 18275894
[TBL] [Abstract][Full Text] [Related]
31. Phase II Trial of Graft-versus-Host Disease Prophylaxis with Post-Transplantation Cyclophosphamide after Reduced-Intensity Busulfan/Fludarabine Conditioning for Hematological Malignancies.
Alousi AM; Brammer JE; Saliba RM; Andersson B; Popat U; Hosing C; Jones R; Shpall EJ; Khouri I; Qazilbash M; Nieto Y; Shah N; Ahmed S; Oran B; Al Atrash G; Ciurea S; Kebriaei P; Chen J; Rondon G; Champlin RE
Biol Blood Marrow Transplant; 2015 May; 21(5):906-12. PubMed ID: 25667989
[TBL] [Abstract][Full Text] [Related]
32. Sequential Conditioning with Thiotepa in T Cell- Replete Hematopoietic Stem Cell Transplantation for the Treatment of Refractory Hematologic Malignancies: Comparison with Matched Related, Haplo-Mismatched, and Unrelated Donors.
Duléry R; Ménard AL; Chantepie S; El-Cheikh J; François S; Delage J; Giannotti F; Ruggeri A; Brissot E; Battipaglia G; Malard F; Belhocine R; Sestili S; Vekhoff A; Delhommeau F; Reman O; Legrand O; Labopin M; Rubio MT; Mohty M
Biol Blood Marrow Transplant; 2018 May; 24(5):1013-1021. PubMed ID: 29337223
[TBL] [Abstract][Full Text] [Related]
33. The Dilemma of Conditioning Intensity: When Does Myeloablative Conditioning Improve Outcomes for Allogeneic Hematopoietic Cell Transplantation.
Solh MM; Solomon SR; Morris LE; Zhang X; Holland HK; Bashey A
Biol Blood Marrow Transplant; 2019 Mar; 25(3):606-612. PubMed ID: 30244109
[TBL] [Abstract][Full Text] [Related]
34. In-vivo T-cell depleted reduced-intensity conditioned allogeneic haematopoietic stem-cell transplantation for patients with acute lymphoblastic leukaemia in first remission: results from the prospective, single-arm evaluation of the UKALL14 trial.
Marks DI; Clifton-Hadley L; Copland M; Hussain J; Menne TF; McMillan A; Moorman AV; Morley N; Okasha D; Patel B; Patrick P; Potter MN; Rowntree CJ; Kirkwood AA; Fielding AK
Lancet Haematol; 2022 Apr; 9(4):e276-e288. PubMed ID: 35358442
[TBL] [Abstract][Full Text] [Related]
35. Who Is a Better Donor for Recipients of Allogeneic Hematopoietic Cell Transplantation: A Young HLA-Mismatched Haploidentical Relative or an Older Fully HLA-Matched Sibling or Unrelated Donor?
Karam E; Laporte J; Solomon SR; Morris LE; Zhang X; Holland HK; Bashey A; Solh MM
Biol Blood Marrow Transplant; 2019 Oct; 25(10):2054-2060. PubMed ID: 31173900
[TBL] [Abstract][Full Text] [Related]
36. [Autologous versus unrelated donor stem cell transplantation for adults with primary acute myeloid leukemia in first remission].
Yao JF; Zhang GX; Yang DL; He Y; Wei JL; Zhai WH; Jiang EL; Zhang RL; Feng SZ; Han MZ
Zhonghua Xue Ye Xue Za Zhi; 2020 May; 41(5):365-372. PubMed ID: 32536132
[No Abstract] [Full Text] [Related]
37. Reduced-intensity allogeneic transplantation using alemtuzumab from HLA-matched related, unrelated, or haploidentical related donors for patients with hematologic malignancies.
Kanda J; Long GD; Gasparetto C; Horwitz ME; Sullivan KM; Chute JP; Morris A; Shafique M; Li Z; Chao NJ; Rizzieri DA
Biol Blood Marrow Transplant; 2014 Feb; 20(2):257-63. PubMed ID: 24269380
[TBL] [Abstract][Full Text] [Related]
38. Total body irradiation-free haploidentical peripheral blood stem cell transplantation compared to related and unrelated donor transplantation in pediatrics with acute lymphoblastic leukemia.
Mardani M; Behfar M; Jafari L; Mohseni R; Naji P; Salajegheh P; Donyadideh G; Hamidieh AA
Pediatr Blood Cancer; 2023 May; 70(5):e30255. PubMed ID: 36815626
[TBL] [Abstract][Full Text] [Related]
39. Comparison of outcomes following transplantation with T-replete HLA-haploidentical donors using post-transplant cyclophosphamide to matched related and unrelated donors for patients with AML and MDS aged 60 years or older.
Bashey ZA; Zhang X; Brown S; Jackson K; Morris LE; Holland HK; Bashey A; Solomon SR; Solh M
Bone Marrow Transplant; 2018 Jun; 53(6):756-763. PubMed ID: 29523888
[TBL] [Abstract][Full Text] [Related]
40. Beneficial Role of Low-Dose Antithymocyte Globulin in Unrelated Stem Cell Transplantation for Adult Patients with Acquired Severe Aplastic Anemia: Reduction of Graft-versus-Host Disease and Improvement of Graft-versus-Host Disease-Free, Failure-Free Survival Rate.
Park SS; Kwak DH; Jeon YW; Yoon JH; Lee SE; Cho BS; Eom KS; Kim YJ; Kim HJ; Lee S; Min CK; Cho SG; Kim DW; Min WS; Lee JW
Biol Blood Marrow Transplant; 2017 Sep; 23(9):1498-1508. PubMed ID: 28554856
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
